Exagen is directing attention to new research results that have demonstrated the value of its Avise test in the differential diagnosis for lupus.
The trial, called Complement Activation Products vs. Standard ANA Testing: Treatment Outcomes, Diagnosis, and Economic Impact in Systemic Lupus Erythematosus (CAPSTONE), utilized multiple external databases and nearly 50,000 patient tests conducted with either Avise or standard-of-care labs.
After comparing diagnosis, treatment, and the cost of care for new patients tested with Avise and those tested with a traditional ANA (tANA) approach, the researchers found that the Avise Lupus test was more clinically effective for both patients who test positive and those who test negative, according to Exagen.
In the first six-month follow-up period for patients who tested negative on both tests, there was a twofold decrease in diagnostic testing costs for those who tested negative with Avise Lupus compared with those who tested negative with tANA. Furthermore, there was 3.5-fold less-frequent repeat testing overall when using Avise Lupus than with tANA, according to the company.
In other findings, Avise Lupus had six-fold higher odds of establishing a new systemic lupus erythematosus diagnosis compared with tANA. Furthermore, Avise Lupus had three-times increased odds of initiating one or more SLE treatments with a positive Avise Lupus result compared with a positive tANA result.
The study was published in the Journal of Managed Care & Specialty Pharmacy.
